By Connor Hart
Sanofi secured accelerated approval from the Food and Drug Administration for its drug Tzield to be used in the treatment of people with the autoimmune and progressive nature of stage 3 type 1 diabetes
The company said Friday that the therapy can delay the decline in endogenous insulin production in children between the ages of eight and 17, who have recently been diagnosed with stage 3 type 1 diabetes.
"Approximately 64,000 people are diagnosed with T1D every year," said Aaron Kowalski, chief executive of Breakthrough T1D. "We are excited that the approval of Tzield in this indication provides a treatment option for certain patients diagnosed in stage 3 T1D, which is when many start experiencing common symptoms of the disease."
Sanofi said the treatment has previously received approvals in the U.K., European Union, China, Australia, Canada, Israel, Saudi Arabia, the United Arab Emirates, Kuwait, Brazil and Switzerland.
Regulatory reviews are ongoing in other jurisdictions around the world, it added.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
June 12, 2026 18:41 ET (22:41 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.